Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18997009 | 0.80 | KCNA3 (0.47) | HDAC1HDAC2KCNA3ALDH1A1 | |
| SCHEMBL3767941 | 0.80 | CA2 (0.38) | CA1CA2MGLLALDH1A1MEN1 | |
| SCHEMBL5959986 | 0.78 | KCNA3 (0.50) | HDAC1HDAC2KCNA3ALDH1A1 | |
| SCHEMBL2057200 | 0.77 | CA2 (0.31) | CA1CA2ALDH1A1 | |
| SCHEMBL2057905 | 0.77 | CA2 (0.31) | CA1CA2 | |
| SCHEMBL2057646 | 0.77 | CA2 (0.31) | CA1CA2 | |
| SCHEMBL2057808 | 0.77 | CA2 (0.31) | CA1CA2ALDH1A1 | |
| SCHEMBL3766974 | 0.75 | RAB9A (0.40) | CA1CA2ALDH1A1NPC1MAPT | |
| SCHEMBL2058048 | 0.75 | CA1 (0.31) | CA1CA2ALDH1A1 | |
| SCHEMBL2057558 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110137063-A1 | COMPOUNDS AND PROCESSES FOR PRODUCTION OF RADIOPHARMACEUTICALS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-09 | — | — | US | disclosed |
| EP-2297070-A2 | COMPOUNDS AND PROCESSES FOR PRODUCTION OF RADIOPHARMACEUTICALS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010000409-A2 | COMPOUNDS AND PROCESSES FOR PRODUCTION OF RADIOPHARMACEUTICALS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137063-A1 | COMPOUNDS AND PROCESSES FOR PRODUCTION OF RADIOPHARMACEUTICALS | PFAS, PFKFB2, PFKFB1 | HDAC1 4737/4885HDAC2 4735/4885CA1 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.